-transparent.png){kind=logo}
Vidarabine, an antiviral chemotherapeutic agent shown to have in vitro activity against the herpes group of viruses, was administered to five patients with brain biopsy-proved herpes simplex virus encephalitis. The mortality in this small number of patients (one of five or 20%) was less than that in most published reports of patients receiving other treatment modalities or no treatment other than supportive measures. No apparent toxicity was found that was attributable to vidarabine. Neuropsychological impairment of varying degree was noted in four surviving patients tested at two months after treatment and again 12 to 21 months later. Progressive improvement had occurred in three.
L H Taber, and
S B Greenberg, and
F I Perez, and
R B Couch
January 1982,
Brain & development,
L H Taber, and
S B Greenberg, and
F I Perez, and
R B Couch
February 1978,
The Medical journal of Australia,
L H Taber, and
S B Greenberg, and
F I Perez, and
R B Couch
January 1982,
Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion,
L H Taber, and
S B Greenberg, and
F I Perez, and
R B Couch
January 1978,
Transactions of the American Neurological Association,
L H Taber, and
S B Greenberg, and
F I Perez, and
R B Couch
September 1982,
No to shinkei = Brain and nerve,
L H Taber, and
S B Greenberg, and
F I Perez, and
R B Couch
April 1982,
Canadian Medical Association journal,
L H Taber, and
S B Greenberg, and
F I Perez, and
R B Couch
September 1977,
Journal of the Medical Association of the State of Alabama,
L H Taber, and
S B Greenberg, and
F I Perez, and
R B Couch
February 1979,
The Medical letter on drugs and therapeutics,
L H Taber, and
S B Greenberg, and
F I Perez, and
R B Couch
May 1981,
The New Zealand medical journal,
L H Taber, and
S B Greenberg, and
F I Perez, and
R B Couch
November 1975,
The Journal of infectious diseases,
